Gossamer Bio submits NDA to US FDA for seralutinib...
Category : Clinical Trial Update 26 September 2026Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commer...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
Newron Provides Update on Phase 3 ENIGMA-TRS 2 Stu...
Category : Clinical Trial Update 26 September 2026Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical co...
Amgen’s Dazodalibep Meets Phase 3 OASIZ 301 Goal i...
Category : Clinical Trial Update 24 September 2026Phase 3 Study Shows Improvement in Systemic Disease Activity Amgen has reported positive topline...
Roche’s Sefaxersen Meets Phase III IMAgINATION Goa...
Category : Clinical Trial Update 24 September 2026Study Shows Significant Reduction in Proteinuria at Week 37 Roche has reported positive prespecif...
Sensorium Therapeutics Reports Positive Phase 1a R...
Category : Clinical Trial Update 23 September 2026Early Study Shows CNS Activity After a Single Dose Sensorium Therapeutics has reported positive r...
Latest Newsletter Post
-
Newron Provides Update on Phase 3 E..
26 September 2026
-
Gossamer Bio submits NDA to US FDA..
26 September 2026
-
Roche’s Sefaxersen Meets Phase III..
24 September 2026
-
Amgen’s Dazodalibep Meets Phase 3 O..
24 September 2026
-
Ulefnersen Meets Phase 3 Endpoint i..
23 September 2026
